ROLE OF GENETIC FACTORS IN THE DEVELOPMENT OF CLOPIDOGREL RESISTANCE AMONG PATIENTS REFERRED FOR PERCUTANEOUS CORONARY INTERVENTIONS

Aim. To study the associations between genetic polymorphisms and the development of clopidogrel resistance in patients referred for percutaneous coronary interventions (PCI).

Material and methods. The study included 84 patients with coronary heart disease (CHD), who underwent planned PCI. Dynamic assessment of platelet aggregation was performed using light transmission aggregometry method (two-channel laser analyser Biola-230LA). The role in the development of inadequate suppression of platelet aggregation during the standard-dose dual antiplatelet therapy (DAT) was investigated for the following genes and polymorphic alleles: CYP2C19 (rs4244285*2, rs4986893*3, rs28399504*, rs56337013*5, and rs12248560*17); CYP2C9 (rs1057910*3); CYP3A4 (rs2242480); CYP2B6 (rs3211371 (5*); CYP3A5 (rs28365083*2 and rs776746); and CYP1A2 (rs762551).

Results. The two study groups demonstrated a statistically significant difference in the prevalence of CYP2C19 rs4244285 (2*) polymorphisms, with an increase in GA and AA genotypes and a reduction in the “wild” GG genotype (Χ2 =11,7; р=0,003). The GA genotype was associated with inadequate suppression of platelet aggregation in patients receiving clopidogrel (75 mg/d) and aspirin (300 mg/d; odds ratio 6,27; 95% confidence interval 1,8–21,69). No significant inter-group differences were observed for other polymorphisms (CYP2C9 (rs1057910*3); CYP3A4 (rs2242480); CYP2B6 (rs3211371 (5*)); CYP3A5 (rs28365083*2, rs776746); and CYP1A2 (rs762551)).

Conclusion. The degree of platelet aggregation in patients on DAT is related to their genetic status. The assessment of genetic polymorphisms can facilitate the choice of optimal therapeutic strategies in clopidogrel-resistant patients. Patients with the CYP2C192* polymorphism are in particular need for an additional correction of the antiaggregant treatment scheme. 

1. Fuster V. Falherapeutic intervention. Thrombosis and Hemostasis 1997; 78 (1): 247–55.

2. Mazurov AV. Physiology and pathology of platelets. Moscow “Literro” 2011; 346 р. Russian (Мазуров А. В. Физиология и патология тромбоцитов. Москва “Литерро” 2011; 346 c).

3. Pavlova TV, Dupliakov DV. Outstanding issues clopidpgrel with acute ischemic heart disease. Effective drug treatment in cardiology and angiology 2010; 2: 44–9. Russian (Павлова Т. В., Дупляков Д. В. Нерешенные вопросы применения клопидогрела при обострении ишемической болезни сердца. Эффективная фармакотерапия в кардиологии и ангиологии 2010; 2: 44–9).

4. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. Thromb Haemost 1994; 72 (2): 313–7.

5. Saw J, Madsen EH, Chan S, et al. The ELAPSE (Evaluation of Long–Term Clopidogrel Antiplatelet and Systemic Anti–Inflammatory Effects) study. JACC 2008; 52 (23): 1826–33.

6. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429–36.

7. Young-Hoon Jeong, MD, In-Suk Kim, Yongwhi Park, MD, et al. Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day. JACC Intv 2010; 3 (7): 731–41.

8. Collet JP, Hulot JS, Anzaha G. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Intv 2011; 4: 392–402.

9. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients UF/NSTEMI (updating the 2007 guideline and replacing the 2011 focused update): a report of the AACF/AHA Task Force on Practice Guidelines. Circulation 2012; 126: 875–910.

10. Hulot JS, Bura A, Villard E, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244–7.

11. Sumarokov AB, Burachkovskaya LB. The use of thienopyridines in patients with atherosclerotic lesions of the arteries. Guide for Physicians/ Moscow/ 2012; p10. Russian (Сумароков А. Б., Бурячковская Л. Б. Применение тиенопиридинов в лечении больных с атеросклеротическим поражением артерий. Руководство для врачей. Москва 2012; 10 c).